Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sorin Visanica

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
American Journal of Hematology|March 18, 2023
Is this really thalassemia?Benoit Thomas, Sorin Visanica, Sophie Poussing, et al.
Bio-Medical Materials and Engineering|July 7, 2012
Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluationVéronique Decot, François Alla, Véronique Latger-Cannard, et al.
Annales De Biologie Clinique|October 19, 2017
From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemiaJulien Decker, Sabine Meyer, Véronique Latger-Cannard, et al.
Genes, Chromosomes & Cancer|March 7, 2006
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9Audrey Sindt, Benedicte Deau, Wajih Brahim, et al.
Blood|December 18, 2012
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experienceMathilde Lamarque, Sophie Raynaud, Raphael Itzykson, et al.
Leukemia & Lymphoma|July 31, 2019
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are availableLynda Foltz, Gian-Matteo Pica, Hacene Zerazhi, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Leukemia Research|August 9, 2012
PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patientsCecile Borel, Nicole Dastugue, Valérie Cances-Lauwers, et al.
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
American Journal of Hematology|March 18, 2023
Is this really thalassemia?Benoit Thomas, Sorin Visanica, Sophie Poussing, et al.
Bio-Medical Materials and Engineering|July 7, 2012
Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluationVéronique Decot, François Alla, Véronique Latger-Cannard, et al.
Annales De Biologie Clinique|October 19, 2017
From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemiaJulien Decker, Sabine Meyer, Véronique Latger-Cannard, et al.
Genes, Chromosomes & Cancer|March 7, 2006
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9Audrey Sindt, Benedicte Deau, Wajih Brahim, et al.
Blood|December 18, 2012
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experienceMathilde Lamarque, Sophie Raynaud, Raphael Itzykson, et al.
Leukemia & Lymphoma|July 31, 2019
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are availableLynda Foltz, Gian-Matteo Pica, Hacene Zerazhi, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Leukemia Research|August 9, 2012
PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patientsCecile Borel, Nicole Dastugue, Valérie Cances-Lauwers, et al.
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Pageof 2